Preparation method and application of respiratory syncytial virus antigen
By removing specific epitopes of RSV F protein and designing new F antigen dimers, the problems of insufficient antibody response and low yield in existing RSV vaccines are solved, and efficient RSV immune protection is achieved.
Patent Information
- Application Number
- CN202310534952.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-12
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2043-05-12
AI Technical Summary
During the conformational change of the existing RSV F protein vaccine, pre-F specific epitope and V epitope are blocked, resulting in the body being unable to produce high-school and active antibodies, and the yield is low and it is difficult to maintain the pre-F conformation and cannot be effective. Prevent RSV infection.
By removing post-F-specific I and IV epitopes and partial sequences of pre-F and post-F shared by pre-F and post-F, the new F antigen sequence was designed and connected into a dimer to maintain pre- F conformation, stimulates the body to produce high-school and active antibodies against pre-F epitope.
It has achieved the maintenance of the pre-F conformation in and out of the body, stimulated the body to produce efficient neutralizing antibodies, and increased the vaccine yield, exceeding 30mg/L, significantly improving the immune protection effect against RSV.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0002] The invention belongs to the field of biomedicine, and specifically relates to a protein for preventing respiratory syncytial virus infection and an application thereof. Background Art
[0003] Respiratory syncytial virus (RSV) is one of the most common pathogens that cause lower respiratory tract infections in infants and young children worldwide. In immunodeficient and immunocompromised elderly people, RSV infection can cause severe clinical symptoms of the lower respiratory tract, thereby increasing the risk of death. Therefore, the development of a safe, effective and low-cost vaccine to prevent RSV infection has become one of the urgent issues that need to be addressed worldwide.
[0004] RSV belongs to the Paramyxoviridae family and the Pneumovirus genus. Its genome is a single-stranded negative-strand virus with a total length of 15.2Kb, encoding 11 viral proteins. There are two glycoproteins, G and F, on the surface of RSV. They are important antigens of RSV and the main targets of neutralizing antibodies. The homology of G protein in different RSV subtypes is only about 50%; while F protein is highly conservative, with only about 10% difference between different RSV subtypes. Therefore, F protein is the main antigen for the design and development of broad-spectrum RSV vaccines.
[0005] During the fusion process between the virus and the host cell membrane, the RSV F protein changes from the pre-F conformation with high potential energy and poor stability to the post-F conformation with low potential energy and relatively stable. The V and V epitopes are blocked, making it impossible for the body to produce antibodies with high neutralizing activity; therefore, the development of RSV vaccines based on pre-F has become a hot topic in the prevention of RSV infection. Although there is no clinically available RSV vaccine, there are several pre-F protein-based vaccines that have entered the clinical trial stage worldwide. These vaccines are all modified based on the monomer structure of the F protein [Krarup A., et al. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nature Communications, 2015, 6: 8143; Crank MC., et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science, 2019, 365, 505-509.], so that it can maintain the conformation of pre-F. However, according to literature reports, these protein vaccines all have problems such as low yield (less than 6 mg / L) [Joyce MG., et al. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. Nature Structural & Molecμlar biology, 2016, 23(9): 811-820.] and inability to always maintain the pre-F conformation [Crank MC., et al. Science, 2019, 365, 505-509.]. Summary of the invention
[0006] In view of the problems existing in the prior art, the inventors have completed the present invention by studying the transformation of the RSV F protein sequence. Specifically, the key design of the present invention is: first, based on the RSV F protein sequence, a new F antigen sequence is obtained by removing the post-F specific I and IV epitope sequences and the III epitope partial sequence shared by pre-F and post-F; second, two new F antigen sequences are connected in series to form a new F antigen dimer. These two designs enable the new F antigen dimer to maintain the pre-F conformation in vitro and in vivo, thereby stimulating the body to produce antibodies that are specific to the pre-F epitope and have high neutralizing activity.
[0007] The present invention provides a method for preparing a respiratory syncytial virus antigen, wherein the respiratory syncytial virus antigen is obtained by expressing the following antigen encoding gene:
[0008] A gene of a RSV F protein monomer from which epitopes I and IV specific to post-F and epitope III common to pre-F and post-F are removed, or two or more thereof are connected in series to obtain a respiratory syncytial virus antigen encoding gene;
[0009] Preferably, according to the F protein sequence of RSV A2 strain (preferably the amino acid sequence shown in SEQ ID NO: 1), the N104-V147 segment (specifically as shown in SEQ ID NO: 2) and the V308-S552 segment (specifically as shown in SEQ ID NO: 3) are removed; a linker sequence (for example, two amino acids of GS) is inserted between T103 and G148 to link them, so as to obtain a gene of an RSV F protein monomer comprising the I and IV epitopes specific to post-F and the III epitope portion shared by pre-F and post-F; or two or more of the obtained new RSV F protein monomers are connected in series to obtain a respiratory syncytial virus antigen encoding gene.
[0010] Preferably, the amino acid sequence from which the post-F-specific I and IV epitopes are removed is F387-D392 (FNPKYD) and K427-S436 (KNRGIIKTFS), and the amino acid sequence of the III epitope portion shared by pre-F and post-F is V40-L45 (VSKGYL);
[0011] The amino acid sequence of the RSV F protein monomer from which the post-F-specific I and IV epitopes and the pre-F and post-F-shared III epitope portion are removed is shown in SEQ ID NO: 4;
[0012] More preferably, the amino acid sequence of the respiratory syncytial virus antigen obtained by connecting two monomers in series is as shown in SEQ ID NO: 5.
[0013] More preferably, a tag sequence and a nucleotide sequence encoding a stop codon are added to the 3' end.
[0014] Specifically, the encoding nucleotide sequence of the tag sequence is a nucleic acid sequence encoding 6 histidines, preferably, as shown in SEQ ID NO:6.
[0015] Furthermore, the nucleotide sequence encoding the stop codon is a stop codon.
[0016] In a specific embodiment, the respiratory syncytial virus antigen encoding gene is expressed in a host cell via a recombinant expression vector to obtain the respiratory syncytial virus antigen; specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell mammalian cell is such as a 293F cell; optionally, it also includes the steps of collecting the cell supernatant after expression and purifying the respiratory syncytial virus antigen.
[0017] The present invention provides a respiratory syncytial virus antigen obtained by the preparation method, preferably an amino acid sequence thereof is as shown in SEQ ID NO: 5, or as shown in SEQ ID NO: 6 after including a tag sequence.
[0018] Further provided is a gene encoding the respiratory syncytial virus antigen.
[0019] The present invention also provides a recombinant expression vector and a recombinant host cell containing the coding gene. Specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell is a mammalian cell such as a 293F cell.
[0020] The present invention also provides an antigen composition comprising the respiratory syncytial virus antigen as an effective ingredient and an adjuvant, preferably the adjuvant is an aluminum adjuvant and an AddVax adjuvant.
[0021] The present invention also provides the use of the respiratory syncytial virus antigen in preparing a reagent for immunizing animals to obtain antibodies.
[0022] The dimer antigen provided by the present invention not only maintains the pre-F conformation in vivo and in vitro, thereby stimulating the body to produce antibodies that are specific to the pre-F epitope and have high neutralizing activity, but also has the advantage of stimulating the body to produce more neutralizing antibodies. In addition, it has been confirmed by experiments that the F antigen dimer of the present invention also has the advantage of high yield (exceeding 30 mg / L in the experiment). BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1 , Superdex 200Increase 10 / 300 (GE) molecular sieve chromatography and electrophoresis of RSV new F antigen dimer.
[0024] Figure 2 , schematic diagram of immunization strategy.
[0025] Figure 3 , the results of RSVF-specific IgG antibody titers induced after cotton rats were immunized with RSV new F antigen dimers.
[0026] Figure 4, the results of in vivo conformational analysis of the protein after cotton rats were immunized with RSV new F antigen dimer (using the Elisa method to infer whether the antigen is pre-F or post-F in vivo).
[0027] Figure 5 , the results of RSV A2 virus neutralizing antibody titers induced after cotton rats were immunized with RSV new F antigen dimer.
[0028] Figure 6 , the results of RSVB9320 virus neutralizing antibody titers induced after cotton rats were immunized with RSV new F antigen dimer.
[0029] Figure 7 , the live virus titers in various tissues of cotton rats immunized with RSV new F antigen dimer and then challenged with the virus.
[0030] Figure 8 , pathological sections of lung tissue of cotton rats immunized with RSV new F antigen dimer and then challenged with the virus. DETAILED DESCRIPTION
[0031] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with specific embodiments and with reference to the accompanying drawings, but it should not be construed as limiting the present invention. The experimental methods used in the examples are conventional methods well known to those skilled in the art unless otherwise specified. The materials, reagents, etc. used in the following examples can be obtained from commercial sources unless otherwise specified.
[0032] The sequence information is as follows:
[0033] SEQ ID NO: 1 (full-length sequence of RSV A2 strain F protein):
[0034] NITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGVGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGVIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLSAIGGYIPEAPRDGQAYVRKDGEWVLLSTFLGGLVPRGS。
[0035] SEQ ID NO: 2 (Amino acid sequence of the N104-V147 segment of the F protein of RSV A2 strain):
[0036] NNRARRELPRFMNYTLNNAKKTNVTLSKKRKRRFLGFLLGV。
[0037] SEQ ID NO: 3 (Amino acid sequence of the V308-S552 segment of the F protein of RSV A2 strain):
[0038] VIDTPCWKLHTSPLCTTNTKEGSNICLTRTDRGWYCDNAGSVSFFPQAETCKVQSNRVFCDTMNSLTLPSEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAIVSCYGKTKCTASNKNRG IIKTFSNGCDYVSNKGVDTVSVGNTLYYVNKQEGKSLYVKGEPIINFYDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLSAIGGYIPEAPRDGQAYVRKDGEWVLLSTFLGGLVPRGS.
[0039] SEQ ID NO: 4 (amino acid sequence of the protein monomer of the present invention):
[0040] NITEEFYQTTASAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVS VLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYG.
[0041] SEQ ID NO: 5 (amino acid sequence of the antigen of the present invention, excluding the tag sequence):
[0042] NITEEFYQTTASAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGNITEEFYQTTASAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYG。
[0043] SEQ ID NO: 6 (Amino acid sequence of the antigen of the present invention, containing a histidine tag):
[0044] NITEEFYQTTASAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSV LTFKVLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGNIT EEFYQTTASAVSKGYLSALRTGWYTSVITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTDLQLLMQSTPATGSGSAIASGVAVCKVLHLEGEVNKIKSALLSTNKAVVSLSNGVSVLTFK VLDLKNYIDKQLLPILNKQSCSIPNIETVIEFQQKNNRLLEITREFSVNAGVTTPVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMCIIKEEVLAYVVQLPLYGHHHHHHH.
[0045] Example 1: Expression and purification of RSV novel F antigen dimer
[0046] According to the F protein sequence of the RSV A2 strain (amino acid sequence as shown in SEQ ID NO: 1), the N104-V147 segment (as shown in SEQ ID NO: 2) and the V308-S552 segment (as shown in SEQ ID NO: 3) were removed; a linker sequence (two amino acids of GS) was inserted between T103 and G148 to obtain the amino acid sequence of the RSV F protein monomer that does not contain the I and IV epitopes specific to post-F and the III epitope part shared by pre-F and post-F (as shown in SEQ ID NO: 4), and then the amino acid sequences of the obtained new RSV F protein monomers were connected in series (as shown in SEQ ID NO: 5), and 6 histidine tags were added to the 3' end (as shown in SEQ ID NO: 6), and the respiratory syncytial virus antigen encoding gene was obtained after codon optimization.
[0047] Then the obtained respiratory syncytial virus antigen encoding gene sequence is cloned into the pCAGGS vector to obtain the pCAGGS-new F antigen dimer plasmid. The plasmid is then transfected into the 293F cell expression system for expression, and the cell supernatant is collected after expression and purified.
[0048] Superdex 200Increase 10 / 300 (GE) molecular sieve was used for chromatography, and the elution peak near 13.5 ml (such as Figure 1 The protein with an elution volume of about 13.5 ml was about 55 Kd under both non-reducing conditions (without DTT) and reducing conditions (with DTT), indicating that the protein obtained in the elution peak was a new F antigen dimer.
[0049] Example 2: Affinity analysis of RSV novel F antigen dimer antibody
[0050] The RSV novel F antigen dimer obtained in Example 1 was fixed on a SM chip using the biomacromolecule interaction analysis system Biacore 8K, and then a variety of antibody Fab fragments targeting different epitopes of the F protein were flowed on the chip surface to measure the affinity between the antigen and the various antibodies.In this example, the I epitope 4D7 [Flynn JA., et al. Stability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein. PLoS ONE, 2016, 11(10):e0164789.], the II epitope Palivazumab [The IMPACT-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 1998, 102, 531-537], the III epitope MPE8 [Gilman MS.et al. Characterization of a prefusion-specific antibody that recognizes a quaternary, cleavage-dependent epitope on the RSV fusion glycoprotein. PLoS Pathogen, 2015, 11:e1005035.], the IV epitope 101F [McLellan JS.etal. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. Journal of Virology, 2010, 84:12236-12244.], the V epitope CR9501 [Gilman MS.et al. Transient opening of trimeric prefusion RSV F proteins. Nature Communications, 2019, 10:2105.] are selected. Epitope Am22 [McLellan JS. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Scinece, 2013, 340(6136): 1113-1117.]. After Biacore 8K analysis, the binding and affinity of RSV novel F antigen dimer with antibody were obtained (as shown in Table 1), and the blank part indicates that the antigen and antibody do not bind.
[0051] Table 1 Binding and affinity of RSV novel F antigen dimer to antibodies
[0052]
[0053] Example 3: RSV novel F antigen dimer immunization experiment on cotton rats
[0054] MF59 (AddaVax used below is an MF59-like adjuvant) and aluminum adjuvant are two commonly used adjuvants approved by SFDA. The present invention selects these two adjuvants as vaccine adjuvants for animal experiments, which will have a direct guiding role in subsequent clinical trials; therefore, the present invention dilutes the antigen obtained in Example 1 with PBS solution to the required concentration, and then mixes them with Alhydrogel aluminum adjuvant and AddVax adjuvant respectively and emulsifies them, and then immunizes female cotton rats aged 6-8 weeks in groups. The immunization grouping, the dosage of the immunogen used in each group, and the adjuvant situation are shown in Table 2, and the blank part indicates "none". The immunization strategy is as follows Figure 2 As shown, each cotton rat received three vaccinations on days 0, 21, and 42 by thigh intramuscular injection, with 200 μl inoculation volume each time, and 100 μl inoculated in both thighs. Orbital blood was collected on days 19, 40, and 56. After the blood samples were allowed to stand, they were centrifuged at 3000 rpm for 10 minutes to obtain serum, which was inactivated in a 56°C water bath for 30 minutes and stored in a -80°C refrigerator for specific antibody titer detection and RSV neutralization experiments.
[0055] Table 2 Immunization groups, immunogen doses and adjuvants used in each group
[0056]
[0057] Example 4: ELISA test to detect antigen-induced specific antibody titer
[0058] The RSV new F antigen dimer protein obtained in Example 1 was diluted to 3 μg / ml with ELISA coating solution and added to the ELISA 96-well plate (Coring, 3590), and 100 μl was added to each well. After standing at 4°C for 12 hours, the coating solution was discarded, PBS was added to wash twice, and 5% skim milk powder prepared with PBS was used as the blocking solution, 100 μl was added to each well, and blocked at 37°C for 1 hour. After blocking, the blocking solution was discarded, and 100 μl of the serum gradient dilution sample obtained in Example 3 was added. The serum sample was diluted 4 times with the blocking solution from 50 times, and a total of 12 gradients were diluted; 100 μl of the blocking solution was directly added to the negative control well. After incubation at 37°C for 1 hour, the supernatant was discarded, and the plate was washed 3 times with PBST, and the chicken anti-cotton rat IgG secondary antibody diluted 1:5000 with the blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 4 times with PBST. Add HRP-conjugated goat anti-chicken IgG tertiary antibody diluted 1:5000 in blocking solution, incubate at 37°C for 0.5 hours, and wash the plate 4 times with PBST. Add TMB colorimetric solution for color development, add 2M hydrochloric acid to terminate the reaction after an appropriate reaction time, and detect OD on a microplate reader. 450 The antibody titer value is defined as the highest serum dilution factor with a reaction value greater than 2.1 times the negative control value. When the reaction value of the lowest dilution factor (detection limit) is still less than 2.1 times the negative control value, the sample titer is defined as half of the lowest dilution factor, i.e. 1:25.
[0059] The results are as follows Figure 3 As shown, during the entire immunization process, the specific antibody levels in the serum of cotton rats in each immunization group increased significantly with the increase in the number of immunizations, among which the antibody levels were the highest after 3 immunizations at a dose of 10 μg aluminum adjuvant and 10 μg AddaVax adjuvant. This result shows that RSV new F antigen dimer can effectively activate the antibody response of cotton rats.
[0060] Example 5: ELISA test to detect the conformation of F neoantigen dimer in vivo
[0061] The RSV new F antigen dimer protein and RSV post-F protein obtained in Example 1 were diluted to 3 μg / ml with ELISA coating solution and added to ELISA 96-well plates (Coring, 3590), with 100 μl added to each well. After standing at 4°C for 12 hours, the coating solution was discarded, PBS was added for washing twice, and 5% skim milk powder prepared in PBS was used as a blocking solution, 100 μl was added to each well, and the plates were blocked at 37°C for 1 hour.
[0062] The serum samples collected after the three immunizations obtained in Example 3 were diluted 4 times with blocking solution from 25 times, and after a total of 12 dilutions, they were mixed with an equal volume of 6μg / ml RSVpost-F protein solution prepared with blocking solution, and incubated at 37°C for 1 hour. Then, they were incubated with a 96-well plate coated with RSV new F antigen dimer protein at 7°C for 1 hour. After discarding the supernatant, the plate was washed 3 times with PBST, and then the chicken anti-cotton rat IgG secondary antibody diluted 1:5000 with blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 4 times with PBST. After adding the HRP-conjugated sheep anti-chicken IgG tertiary antibody diluted 1:5000 with blocking solution, the plate was incubated at 37°C for 0.5 hours, and the plate was washed 4 times with PBST. TMB colorimetric solution was added for color development, and 2M hydrochloric acid was added to terminate the reaction after an appropriate reaction time, and the OD was detected on an enzyme reader. 450 Read the value.
[0063] The serum samples collected after the three immunizations obtained in Example 3 were diluted 4 times with blocking solution from 50 times, and after a total of 12 dilutions, they were directly incubated at 37°C with a 96-well plate coated with RSV post-F protein that had been washed with PBS. After 1 hour, the supernatant was discarded, and the plate was washed 3 times with PBST. Then, the chicken anti-cotton rat IgG secondary antibody diluted 1:5000 with blocking solution was added. After incubation at 37°C for 1 hour, the plate was washed 4 times with PBST. After adding the HRP-conjugated sheep anti-chicken IgG tertiary antibody diluted 1:5000 with blocking solution, incubated at 37°C for 0.5 hour, and then the plate was washed 4 times with PBST. TMB colorimetric solution was added for color development. After an appropriate reaction time, 2M hydrochloric acid was added to terminate the reaction, and the OD was detected on an enzyme reader. 450 Read the value.
[0064] The calculation method of antibody titer is the same as that in Example 3. The data of specific binding antibodies in the three-free serum (three-free), the data of direct binding of serum and post-F (direct), and the data of binding of serum and post-F to RSV F protein after competition (competition) in Example 3 are jointly analyzed (as shown in Figure 2). Figure 4 The three-immunity data were significantly different from the direct data, but not statistically different from the competition data. This result shows that the RSV novel F antigen dimer protein exists in the body in the form of pre-F. Although the direct binding data show that there is a certain proportion of antibodies in the serum that can bind to post-F, it is because pre-F and post-F share epitopes, such as the known II and IV epitopes, and there may be some unknown common binding antibodies.
[0065] Example 6: Virus Neutralization Experiment with Immune Serum
[0066] The serum obtained in Example 3 was diluted at an initial 1:5, and then diluted 4-fold in 7 gradients, and then mixed with an equal volume of 200 TCID 50RSV A2 and RSV B9320 were mixed. After incubation at 37°C for 1 hour, 100 μl of the mixture was added to a 96-well plate with a HEp-2 cell coverage of about 70%. After incubation at 37°C for 2 hours, the mixture was discarded and 100 μl of 2% FBS DMEM medium was added. After incubation at 37°C for 4 days, the medium was discarded, the cells were washed twice with PBS, and ice-cold 80% acetone solution was added to fix for 20 minutes. The supernatant was discarded, PBS was added to wash twice, and 5% skimmed milk powder prepared with PBS was used as the blocking solution. 100 μl was added to each well and blocked at 37°C for 1 hour. After blocking, the blocking solution was poured out, and 100 μl / well of the Palivazumab primary antibody solution prepared with the blocking solution at a concentration of 3 μg / ml was added. After incubation at 37°C for 1 hour, the plate was washed 3 times with PBST. Add HRP-conjugated goat anti-human IgG secondary antibody diluted 1:5000 in blocking solution, incubate at 37°C for 1 hour, and wash the plate 4 times with PBST. Add TMB colorimetric solution for color development, add 2M hydrochloric acid to terminate the reaction after an appropriate reaction time, and detect OD on an enzyme reader. 450 The antibody titer value is defined as the highest serum dilution factor with a reaction value greater than 2.1 times the negative control value. When the reaction value of the lowest dilution factor (detection limit) is still less than 2.1 times the negative control value, the sample titer is defined as half of the lowest dilution factor, i.e. 1:25.
[0067] The results are as follows Figure 5 , Figure 6 As shown, during the entire immunization process, the neutralizing antibody level in the serum of cotton rats in each immunization group increased significantly with the increase in the number of immunizations, among which the antibody level was the highest after 3 immunizations at a dose of 10 μg aluminum adjuvant and 3 μg AddaVax adjuvant. This result shows that RSV new F antigen dimer can effectively stimulate cotton rats to produce neutralizing antibodies and achieve immune protection for the body.
[0068] Example 7: Cotton rat challenge protection experiment
[0069] The cotton rats in Example 3 were infected with 10 5 TCID 50 RSV A2 virus (such as Figure 2 The animals were killed 5 days later, and the lungs, trachea, and cheekbones were removed. The tissues were homogenized and used for virus titer (TCID 50 ) test. The results are as follows Figure 7 As shown, compared with the PBS control group, the viral load in various tissues of cotton rats in the vaccine group was significantly reduced, showing a good protective effect.
[0070] Example 8: Protective effect of vaccine on cotton rat tissues
[0071] The lung and trachea samples in Example 7 were immersed in 4% paraformaldehyde solution for fixation. After the lung tissue samples were sliced, hematoxylin-eosin staining was used to observe the lung lesions. Figure 8 As shown, the lungs of cotton rats in the PBS group had inflammatory cell infiltration, alveolitis and other injuries. In the immunized cotton rats, whether using aluminum adjuvant or AddaVax adjuvant, the lung damage caused by virus attack was greatly alleviated, showing mild damage, with clear alveoli and only a few inflammatory cell infiltrations; these mild lung injuries were mainly caused by a large one-time attack dose. The above results show that RSV new F antigen dimer as a vaccine can greatly alleviate the lung damage caused by RSV A2 virus infection.
Claims
1. A method for preparing a respiratory syncytial virus antigen, characterized in that: The respiratory syncytial virus antigen is expressed by the following antigen encoding gene: A gene of a RSV F protein monomer from which epitopes I and IV specific to post-F and epitope III common to pre-F and post-F are removed, or two or more thereof are connected in series to obtain a respiratory syncytial virus antigen encoding gene; Preferably, according to the F protein sequence of the RSV A2 strain (preferably the amino acid sequence shown in SEQ ID NO: 1), the N104-V147 segment (specifically as shown in SEQ ID NO: 2) and the V308-S552 segment (specifically as shown in SEQ ID NO: 3) are removed; a linker sequence (for example, two amino acids GS) is inserted between T103 and G148 to link them, so as to obtain a gene of an RSV F protein monomer comprising the I and IV epitopes specific to post-F and the III epitope portion shared by pre-F and post-F; or two or more of the obtained new RSV F protein monomers are connected in series to obtain a respiratory syncytial virus antigen encoding gene.
2. The preparation method according to claim 1, characterized in that The amino acid sequences of epitopes I and IV that are specific to post-F removed are F387-D392 (FNPKYD) and K427-S436 (KNRGIIKTFS), and the amino acid sequence of the epitope III portion shared by pre-F and post-F is V40-L45 (VSKGYL); The amino acid sequence of the RSV F protein monomer from which the post-F-specific I and IV epitopes and the pre-F and post-F-shared III epitope portion are removed is shown in SEQ ID NO: 4; Preferably, the amino acid sequence of the respiratory syncytial virus antigen obtained by connecting two monomers in series is as shown in SEQ ID NO:
5.
3. The preparation method according to claim 1, characterized in that: A tag sequence and a nucleotide sequence encoding a stop codon are also added at the 3' end.
4. The preparation method according to claim 3, characterized in that: The coding nucleotide sequence of the tag sequence is a nucleic acid sequence encoding 6 histidines, preferably, as shown in SEQ ID NO: 6; Furthermore, the nucleotide sequence encoding the stop codon is a stop codon.
5. The preparation method according to any one of claims 1 to 3, characterized in that: The respiratory syncytial virus antigen encoding gene is expressed in a host cell via a recombinant expression vector to obtain the respiratory syncytial virus antigen; specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell mammalian cell is such as a 293F cell; optionally, it also includes the steps of collecting the cell supernatant after expression and purifying the respiratory syncytial virus antigen.
6. The respiratory syncytial virus antigen obtained by the preparation method according to any one of claims 1 to 5, preferably having an amino acid sequence as shown in SEQ ID NO: 5, or as shown in SEQ ID NO: 6 after including a tag sequence.
7. The gene encoding the respiratory syncytial virus antigen as claimed in claim 6.
8. A recombinant expression vector and a recombinant host cell containing the coding gene according to claim 7, specifically, the starting vector of the recombinant vector is a mammalian cell expression vector such as a pCAGGS vector, and the host cell is a mammalian cell such as a 293F cell.
9. An antigen composition comprising the respiratory syncytial virus antigen as claimed in claim 6 as an effective ingredient and an adjuvant, wherein the adjuvant is preferably an aluminum adjuvant and AddVax adjuvant.
10. Use of the respiratory syncytial virus antigen according to claim 6 in preparing a reagent for immunizing an animal to obtain antibodies.
Citation Information
Patent Citations
Prefusion RSV F proteins and their use
CN105473604A
RSV f protein mutants
CN108738312A
Recombinant respiratory syncytial virus chimeric vaccine, as well as preparation method and application thereof
CN111138550A
Coding gene of respiratory syncytial virus antigen protein, antigen protein, recombinant vector, vaccine and application
CN115786369A
Pre-fusion RSV f antigens
US20140248314A1
